** U.S.-listed shares of Zymeworks Inc up 5% at $18.40
** The Canada-based drug developer says it has earned a milestone payment of $2 mln in connection with a research and license pact with Merck & Co
** Merck has a worldwide, royalty-bearing license to research, develop and commercialize certain therapies for which Zymeworks is eligible to receive additional milestone payments and royalties on product sales
** ZYME says it has strategic partnerships with 9 biopharma companies
** Earlier this month, the co announced expansion of a similar pact with British drugmaker GlaxoSmithKline Plc
** Up to Tuesday’s close, ZYME had risen 19.4% YTD (Reporting by Manojna Maddipatla)
Our Standards: The Thomson Reuters Trust Principles.